0000899243-18-017523.txt : 20180620 0000899243-18-017523.hdr.sgml : 20180620 20180620204457 ACCESSION NUMBER: 0000899243-18-017523 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180620 FILED AS OF DATE: 20180620 DATE AS OF CHANGE: 20180620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZDRAVESKI ZORAN CENTRAL INDEX KEY: 0001741285 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38541 FILM NUMBER: 18910730 MAIL ADDRESS: STREET 1: C/O MAGENTA THERAPEUTICS STREET 2: 50 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Magenta Therapeutics, Inc. CENTRAL INDEX KEY: 0001690585 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 857-201-2700 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2018-06-20 0 0001690585 Magenta Therapeutics, Inc. MGTA 0001741285 ZDRAVESKI ZORAN C/O MAGENTA THERAPEUTICS, INC. 50 HAMPSHIRE STREET CAMBRIDGE MA 02139 0 1 0 0 See Remarks Common Stock 135449 D Stock Option (Right to Buy) 7.71 2028-01-30 Common Stock 17685 D Stock Option (Right to Buy) 9.49 2028-05-08 Common Stock 133514 D Series C Preferred Stock Common Stock 4643 D This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2018. This option shall vest and become exercisable in 48 equal monthly installments beginning on the date of effectiveness of the Issuer's Registration Statement on Form S-1. Each share of Series C Preferred Stock is convertible into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a 2.58398:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series C Preferred Stock will convert into shares of Common Stock of the Issuer. The Series C Preferred Stock has no expiration date. Secretary & Chief Legal Officer Exhibit 24.1: Power of Attorney /s/ Zoran Zdraveski 2018-06-20 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

                                    Power of Attorney

    Know all by these presents, that the undersigned hereby constitutes and
appoints each of Jason Gardner and Cindy Driscoll, signing singly, and with full
power of substitution, as the undersigned's true and lawful attorney-in-fact to:

          (1) execute for and on behalf of the undersigned, in the undersigned's
          capacity as an officer and/or director of Magenta Therapeutics, Inc.,
          a Delaware corporation (the "Company"), from time to time the
          following Securities and Exchange Commission (the "SEC") forms: Forms
          3, 4, and 5 in accordance with Section 16(a) of the Securities
          Exchange Act of 1934, as amended (the "Exchange Act"), and the rules
          thereunder;

          (2) do and perform any and all acts for and on behalf of the
          undersigned which may be necessary or desirable to complete and
          execute any such Form 3, 4, or 5, complete and execute any amendment
          or amendments thereto, and timely file such form with the SEC and any
          stock exchange or similar authority; and

          (3) take any other action of any type whatsoever in connection with
          the foregoing which, in the opinion of such attorney-in-fact, may be
          of benefit to, in the best interest of, or legally required by, the
          undersigned, it being understood that the documents executed by such
          attorney-in-fact on behalf of the undersigned pursuant to this Power
          of Attorney shall be in such form and shall contain such terms and
          conditions as such attorney-in-fact may approve in such attorney-in-
          fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an officer of
the Company. This Power of Attorney may be filed with the SEC as a confirming
statement of the authority granted herein.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 15 day of June, 2018.

                /s/ Zoran Zdraveski
              --------------------------

Printed Name:   Zoran Zdraveski
              --------------------------